Smith Karen L.
SEC-identified person · CIK 1639637 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Context Therapeutics Inc. CNTX | Director | filed 2024 - 2026 |
| Skye Bioscience, Inc. SKYE | Director | filed 2024 - 2026 |
| Sangamo Therapeutics, INC SGMO | Director | filed 2018 - 2025 |
| Aurinia Pharmaceuticals Inc. AUPH | Director | filed 2023 - 2024 |
| Tourmaline Bio, Inc. TRML | Director | filed 2022 - 2023 |
| Quince Therapeutics, Inc. QNCX | Chief Medical Officer | filed 2022 - 2023 |
| Antares Pharma, INC. ATRS | Director | filed 2019 - 2022 |
| Acceleron Pharma INC XLRN | Director | filed 2017 - 2021 |
| Emergent Biosolutions Inc. EBS | EVP, Chief Medical Officer | filed 2020 - 2021 |
| Jazz Pharmaceuticals plc JAZZ | Global Head of R&D and CMO | filed 2015 - 2018 |
| Sucampo Pharmaceuticals, Inc. SCMP | Director | filed 2017 - 2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.